JP2021512869A5 - - Google Patents

Download PDF

Info

Publication number
JP2021512869A5
JP2021512869A5 JP2020541731A JP2020541731A JP2021512869A5 JP 2021512869 A5 JP2021512869 A5 JP 2021512869A5 JP 2020541731 A JP2020541731 A JP 2020541731A JP 2020541731 A JP2020541731 A JP 2020541731A JP 2021512869 A5 JP2021512869 A5 JP 2021512869A5
Authority
JP
Japan
Prior art keywords
composition
sodium
amount
total weight
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512869A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050076 external-priority patent/WO2019148247A1/en
Publication of JP2021512869A publication Critical patent/JP2021512869A/ja
Publication of JP2021512869A5 publication Critical patent/JP2021512869A5/ja
Pending legal-status Critical Current

Links

JP2020541731A 2018-02-02 2019-02-01 経口製剤及びその使用 Pending JP2021512869A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900324 2018-02-02
AU2018900324A AU2018900324A0 (en) 2018-02-02 Oral Formulations and Uses Thereof
PCT/AU2019/050076 WO2019148247A1 (en) 2018-02-02 2019-02-01 Oral formulations and uses thereof

Publications (2)

Publication Number Publication Date
JP2021512869A JP2021512869A (ja) 2021-05-20
JP2021512869A5 true JP2021512869A5 (https=) 2022-01-11

Family

ID=67477795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541731A Pending JP2021512869A (ja) 2018-02-02 2019-02-01 経口製剤及びその使用

Country Status (9)

Country Link
US (1) US20200368166A1 (https=)
EP (1) EP3746078A4 (https=)
JP (1) JP2021512869A (https=)
CN (1) CN111670035A (https=)
AU (1) AU2019215802A1 (https=)
CA (1) CA3089656A1 (https=)
MX (1) MX2020008137A (https=)
WO (1) WO2019148247A1 (https=)
ZA (1) ZA202005143B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008138A (es) 2018-02-02 2020-10-19 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Formulaciones parentales y usos de estas.
US12351557B2 (en) 2018-12-24 2025-07-08 Eustralis Pharmaceuticals Limited Chemical compound manufacture, new salt form, and therapeutic uses thereof
WO2021035289A1 (en) * 2019-08-23 2021-03-04 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
CN114306394A (zh) * 2020-09-30 2022-04-12 杭州远大生物制药有限公司 微生物制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
JP2010533655A (ja) * 2007-07-19 2010-10-28 アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド 頭蓋内圧を低下させるための方法
EP2217217B1 (en) * 2007-11-23 2018-05-30 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
ES2623503T3 (es) * 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
IN2013MU02031A (https=) * 2013-06-14 2015-06-05 Novoexcipients Pvt Ltd
AU2014286926A1 (en) * 2013-07-02 2015-12-17 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-II
JP6963896B2 (ja) * 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Cftr媒介性疾患の処置のための医薬組成物を調製する方法
JP6336078B2 (ja) * 2013-12-03 2018-06-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 医薬組成物

Similar Documents

Publication Publication Date Title
JP2021512869A5 (https=)
TWI583384B (zh) 包含4-胺基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸鹽單水合物之醫藥組合物
JP2015091822A5 (https=)
JP2021001196A5 (https=)
JP2021512117A5 (https=)
JP2011500583A5 (https=)
JP2018507200A5 (https=)
JP2016537347A5 (https=)
JP6301934B2 (ja) チカグレロルを含む固形経口医薬製剤
JP7665702B2 (ja) アキシチニブを含有する医薬組成物
JP2019526591A5 (https=)
JP2023536667A5 (https=)
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
US20180064653A1 (en) Pharmaceutical compositions of dimethyl fumarate
US20140010883A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
JP2023551712A5 (https=)
JP2023548855A5 (https=)
WO2016079687A1 (en) Oral pharmaceutical composition of teriflunomide
US11730753B2 (en) Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride
JP7226697B2 (ja) ブロナンセリン含有錠剤
JP2018145095A (ja) エルロチニブ塩酸塩含有医薬組成物
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
JP2015221782A (ja) モンテルカストナトリウム含有製剤
JP2025535941A5 (https=)
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法